Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial

PHASE3CompletedINTERVENTIONAL
Enrollment

91

Participants

Timeline

Start Date

December 30, 2018

Primary Completion Date

January 30, 2021

Study Completion Date

January 30, 2021

Conditions
Thoracic DiseasesPostoperative PainOpioid Use
Interventions
DRUG

Liposomal bupivacaine

5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.

DRUG

Bupivacaine Injection

5cc of drug preparation will be percutaneously injected into each intercostal space 3-10 under direct intrathoracic vision and subcutaneously into each surgical wound at the conclusion of the surgery.

Trial Locations (1)

94143

University of California, San Francisco, San Francisco

All Listed Sponsors
lead

University of California, San Francisco

OTHER

NCT03508830 - Minimally Invasive Thoracic Surgery Intercostal Nerve Block Trial | Biotech Hunter | Biotech Hunter